Overview of Polymyxin B

This section defines Polymyxin B by its core identity, origin, classification, and general function, adhering strictly to non-clinical details.

Property	Description
Active ingredient	Polymyxin B sulfate
Form	Solution, ointment, or powder for injection
Pharmacological class	Antibiotic, Antimicrobial agent (Polymyxin class)
Common use	Killing susceptible Gram-negative bacteria
Origin	Natural product derived from Bacillus polymyxa

Polymyxin B: Definition and Pharmacological Classification

Polymyxin B is an antibiotic medication formally categorized as an antimicrobial agent belonging to the unique Polymyxin class of drugs. It is used to fight infections by directly killing susceptible bacteria. Polymyxin B is primarily a natural product, chemically defined as a polypeptide antibiotic and a cyclic lipopeptide derived from the soil bacterium Bacillus polymyxa. It is typically formulated and administered as Polymyxin B sulfate to ensure optimal stability and solubility. Polymyxin B is recognized as an established and essential anti-infective agent and is designated as a key agent against specific multidrug-resistant pathogens. The distinction of the Polymyxin class lies in its unique, detergent-like mechanism which targets the outer protective layers of bacteria.

Composition, Available Forms, and General Purpose

The medication's active ingredient is Polymyxin B sulfate, which is formulated into several high-level dosage form(s) to ensure effective delivery. These preparations include a sterile powder for injection for systemic use, an aqueous solution for ophthalmic solution (eye) and otic solution (ear) forms, and a topical ointment generally prepared with a petrolatum base for skin application. A typical use scenario involves combining Polymyxin B with other antibiotics, such as Neomycin and Bacitracin, to create a combination product designed for broad-spectrum local use. The general therapeutic purpose of this agent is to act as a potent bactericidal agent with a specialized action. This agent provides a targeted method to eliminate susceptible Gram-negative bacteria. This specialized function positions Polymyxin B as a clinically important, although targeted, antibiotic resource.

Regulatory References

What side effects are possible with Polymyxin B?

Possible Side Effects and Safety Information

The official safety profile of Polymyxin B, as documented by regulatory authorities, focuses primarily on dose-limiting toxicities, particularly when the drug is administered systemically (by injection).

Category	Official Regulatory Classification (High-Level)
Primary Safety Concerns	Nephrotoxicity (Kidney damage/impairment) and Neurotoxicity (Nerve effects)

. | | Frequency | Common with systemic use: Nephrotoxicity. Uncommon: Neurotoxicity. Frequency Not Defined: Hypersensitivity reactions. | | Affected Systems | Renal and Urinary Disorders, Nervous System Disorders, Ear and Labyrinth Disorders (Ototoxicity), Immune System Disorders. |

Nephrotoxicity is the principal dose-dependent toxicity, meaning the risk increases with higher doses, and it is the most common adverse reaction associated with systemic use. Neurotoxicity may include symptoms like paresthesia (numbness or tingling), dizziness, and slurred speech. These effects are often associated with elevated levels of the drug in the bloodstream.

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious adverse reactions, notably the potential for Acute Renal Failure and Respiratory Paralysis resulting from neuromuscular blockade. Anaphylaxis is also recognized as a potential severe hypersensitivity reaction. Safety considerations explicitly state that patients with pre-existing renal impairment are at a heightened risk for both kidney and nerve toxicity. Caution is required when combining Polymyxin B with other medications known to cause nephrotoxicity or neurotoxicity due to the enhanced risk of compounding these serious adverse effects. The possibility of systemic absorption is noted even with local (topical) use on compromised skin.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the systemic overdose profile of Polymyxin B through potential nephrotoxicity (kidney) and neurotoxicity (nerve) effects. Overexposure is generally associated with achieving high drug serum levels, often occurring in patients with impaired renal function due to reduced drug clearance.

Documented Manifestations and Severe Outcomes

System	Documented Clinical Signs
Renal	Azotemia, albuminuria, diminishing urine output, and a rising blood urea nitrogen (BUN) and creatinine level.
Neurological	Paresthesia (tingling/numbness), dizziness, ataxia, and blurring of vision.

The most severe and potentially life-threatening outcome is respiratory paralysis, which may arise from neuromuscular blockade. Acute kidney injury is also a significant complication of severe overexposure.

Required Emergency Actions

The official guidance mandates that the drug must be discontinued immediately if laboratory evidence of toxicity, such as a rise in BUN, is observed, or if neurological signs like paresthesia appear. Seek immediate medical attention for any signs of respiratory paralysis or severe respiratory depression. If respiratory function is compromised, respiration should be assisted as required (e.g., assisted ventilation).

Treatment is officially defined as symptomatic and supportive, and no specific antidote is known. Continuous patient monitoring of both renal function and neurological status is required.

Therapeutic Uses of Polymyxin B

Polymyxin B is a medication with a highly targeted therapeutic scope, primarily focused on addressing conditions caused by specific susceptible bacteria that create severe or persistent symptomatic conditions across different areas of the body. Usage is indicated for several critical conditions.

Therapeutic Support Across Key Domains

This medication is applied across domains where additional symptomatic support is needed. Polymyxin B is applicable within clinical settings that involve acute or disruptive symptom patterns, such as severe infections including sepsis and bacteremia, and is commonly used in conditions involving inflammatory or irritative processes, such as bacterial conjunctivitis and otitis externa. It is also relevant for managing minor trauma, such as cuts, scrapes, and abrasions.

The primary benefit is that it provides support that helps ease the overall symptom burden.

“This agent contributes to easing the overall symptom load in situations where patients experience inflammatory or irritative states.”

Quick Fact: Core Therapeutic Benefit

Polymyxin B assists with easing local discomfort and contributes to improving day-to-day comfort during symptomatic periods related to external eye and ear infections, and it helps manage the risk of symptoms related to bacterial growth in minor skin injuries.

Eligibility and Restrictions for Use

Who Can and Cannot Use Polymyxin B: Eligibility Profile

The eligibility profile for Polymyxin B is strictly defined by government regulatory documents, focusing on patient status and clinical supervision.

Contraindications and Restrictions

Classification	Population/Condition	Restriction Detail
Absolute Contraindicated	Prior Hypersensitivity	Must not be used in patients with a history of allergy to polymyxins or formulation components.
Absolute Contraindicated	Myasthenia Gravis	Should not be used due to risk of neuromuscular blockade (cited in some official monographs).
Conditional Use	Renal Impairment	Patients with pre-existing renal damage are eligible but require a mandatory dose reduction and close monitoring of renal function.
Conditional Use	Systemic Administration	Intravenous, intramuscular, and intrathecal routes are authorized only for hospitalized patients under constant physician supervision.

Special Populations

Pregnancy and Lactation: Safety in human pregnancy has not been established. Use is only considered if the expected maternal benefit outweighs the possible fetal risk. It is unknown if the drug is excreted into breast milk.
Pediatric Use: Intramuscular administration is not routinely recommended in children and infants due to pain at the injection site, though systemic use is otherwise established.

What should I know about interactions with other medicines?

The official regulatory documents for Polymyxin B establish a structured interaction profile based on two major pharmacodynamic risks: additive nephrotoxicity and neurotoxicity. This structure governs explicit constraints for co-administration.

Pharmacodynamic Interaction Profile

Category	Official Interaction Constraint
Additive Nephrotoxicity Risk	The concurrent or sequential use of other nephrotoxic medicinal products must be avoided. Interacting agents include certain aminoglycoside antibiotics (e.g., Gentamicin, Amikacin, Tobramycin), systemic Bacitracin, Colistin, Cisplatin, and Vancomycin.
Neuromuscular Blockade Potentiation	Co-administration with neuromuscular blocking agents or specific anesthetic agents is restricted. This interaction can result in severe neurotoxicity due to the potentiation of neuromuscular blockade, with a risk of respiratory paralysis.

Population and Disease State Constraints

The use of Polymyxin B is formally contraindicated in the disease state of Myasthenia Gravis due to the critical, documented risk of enhanced neuromuscular blockade. Additionally, the overall risk and severity of all toxic interactions are amplified in patients with impaired renal function because reduced drug clearance leads to a cumulative systemic effect. A specific population interaction note states that the use of high-dose Furosemide (>20 mg/day) has been officially associated with an increased risk of Polymyxin B-associated kidney injury.

Mechanism of Action

Membrane Disruption and Cell Lysis: A Physical Attack

Polymyxin B exerts its primary effect as a physical membrane disrupter, where its polycationic groups target and displace stabilizing cations from the Lipopolysaccharide (LPS) outer membrane of Gram-negative bacteria. This initial interaction collapses the microbial barrier, allowing the drug to insert itself and rapidly cause leakage of essential cellular contents like ions and ATP. The subsequent loss of microbial homeostasis results in direct bactericidal action against susceptible Gram-negative organisms.

Endotoxin Neutralization and Anti-Toxin Activity

A unique, secondary mechanism involves the ability of Polymyxin B to chemically sequester and neutralize circulating Endotoxin (LPS) released upon bacterial cell death. By binding to the endotoxin, the mechanism inhibits the activation of host immune cells, which is the physiological consequence of preventing toxin binding to immune receptors. This action is a component of the drug's overall pharmacodynamic effect profile.

Mechanistic Limitations and Specificity

The mechanism is intrinsically limited by the target structure, making it physiologically constrained against Gram-positive bacteria, which lack the requisite LPS outer membrane. The mechanism's specificity focuses the drug's activity on susceptible Gram-negative organisms and applies only where the target LPS structure has not been chemically modified by microbial resistance factors.

Dosage and Administration Information

How to Use Polymyxin B: Official Administration Guidelines

This section outlines standardized usage parameters for Polymyxin B.

Approved Administration Routes

Polymyxin B is administered via several routes depending on the intended use, including:

Parenteral: Intravenous (IV) Drip, Intramuscular (IM) injection (though not routinely recommended due to local pain), and Intrathecal (IT) injection (for central nervous system use).
Topical: Ophthalmic instillation (drops/ointment) and Otic administration (ear drops, usually in combination products).

Dosing and Frequency

Dosage is strictly calculated based on the patient's body weight in units/kilogram (units/kg) and specific regimen:

Route	Standard Adult/Child Dose (Normal Renal Function)	Frequency
Intravenous (IV)	15,000 to 25,000 units/kg/day	Divided and administered every 12 hours (q12hr)
Intrathecal (IT)	50,000 units (Initial/Maintenance)	Initial: Daily for 3–4 days; Maintenance: Every other day (qODay)

For patients with kidney impairment, the intravenous and intramuscular daily dosage must be reduced. Infants may receive a higher total daily dose, up to 40,000 units/kg/day.

Preparation and Procedural Steps

Polymyxin B powder requires reconstitution with specific diluents and volumes depending on the route:

IV Drip: The reconstituted solution must be further diluted in a large volume (e.g., 300 to 500 mL of 5% Dextrose Injection) and administered as a slow continuous infusion.
Intrathecal: The powder is dissolved to achieve a specific concentration (e.g., 50,000 units/mL) in Sodium Chloride Injection.

Parenteral administration (IV, IM, IT) is restricted to hospitalized patients. For Intrathecal use, maintenance treatment continues for at least two weeks after the required clinical criteria are met.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Polymyxin B

Evidence for Use in Treating Severe Systemic Infections

Research for systemic Polymyxin B was studied for severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria in critically ill patients. Studies primarily included observational cohort studies and systematic reviews, along with a limited number of Randomized Controlled Trials (RCTs). Researchers monitored critical endpoints, including the assessment of survival rates and measures of symptom resolution.

Findings regarding these endpoints have been mixed across the compiled research, and the reliance on observational data means the evidence quality varies across studies. Because these studies often involve critically ill patients, the results apply only to the populations studied.

Evidence for Topical and Localized Use

Polymyxin B was evaluated in RCTs for Acute Otitis Externa (outer ear infections) and in various clinical trials for Bacterial Conjunctivitis (eye infections) and minor skin injuries.

For these localized conditions, the research mainly focused on topical combination products (e.g., in ear drops, ointments, or eye drops). Studies report how symptoms evolved in the observed populations, such as the healing effectiveness of topical ointments and the symptom resolution in eye and ear infections. There is limited direct information available on the contribution of Polymyxin B when used as a single agent for these indications, as most data pertains to the combination formulations.

Research Gaps and Uncertainty

Uncertainty in the systemic research surrounds the limited quantity of high-quality RCTs. The follow-up durations were limited across nearly all studies, typically covering 14 to 28 days for systemic use and short-term periods for topical use. This means that long-term effects are not fully established for any indication.

Specific data on certain special patient groups, such as pregnant populations or those with rare immune-compromised states, evidence is limited. The existing research primarily provides context about group patterns and highlights areas where future research is ongoing.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Polymyxin B (FAQ)

Q: Is Polymyxin B only used in combination with other medicines?

The official product information indicates that Polymyxin B Injection is approved for systemic use as a single agent to treat certain serious bacterial infections. However, the drug is also commonly found as a key ingredient in combination products designed for topical applications, such as in ointments or ear drops.

Q: Does Polymyxin B interact with blood pressure medication?

Regulatory warnings highlight that caution or avoidance is necessary when co-administering Polymyxin B with other nephrotoxic (potentially kidney-damaging) or neurotoxic (potentially nerve-damaging) medications. Since some blood pressure medications fall into these classes, the prescribing physician reviews all concurrent medications.

Q: How does Polymyxin B differ from Polymyxin E (Colistin)?

According to official data, the primary difference lies in how they are administered. Polymyxin B is given as the active drug (Polymyxin B sulfate). In contrast, Polymyxin E (Colistin) is typically given as an inactive prodrug, which the body must convert into its active form.

Q: What is the main difference between Polymyxin B and other common antibiotics?

Polymyxin B is classified as a unique polypeptide antibiotic. Its unique action targets the outer membrane of susceptible bacteria, distinguishing it from antibiotics with other modes of action.

Q: Why is Polymyxin B sometimes referred to as a 'last resort' drug?

Official information indicates that Polymyxin B is typically reserved as a treatment option for multidrug-resistant (MDR) Gram-negative bacterial infections. It is used when other antibiotics have been found to be ineffective or inappropriate against the specific organism causing the illness.

Q: Does Polymyxin B treat fungal or viral infections?

No, official regulatory documents confirm that Polymyxin B is an antibacterial drug. It is used exclusively to treat infections caused by susceptible bacteria and is not effective against fungal, viral, or Gram-positive infections.

Q: How quickly does Polymyxin B start to show an effect after use?

The regulatory information provides pharmacological data, indicating that the drug concentration may reach its peak in the blood within approximately two hours after an intramuscular (IM) injection. The specific time until clinical symptom relief is achieved is not consistently stated across official documents.

Q: Do the side effects of Polymyxin B typically go away after treatment ends?

Studies cited in regulatory reviews suggest that the neurotoxic side effects associated with the drug are usually mild. Official information indicates these effects may resolve when the medication is discontinued, and notes that kidney effects (nephrotoxicity) may also be reversible.

Q: Is it common to feel tired while using Polymyxin B?

The official safety profile includes central nervous system effects classified as neurotoxicity. These effects include reported symptoms such as drowsiness (somnolence) and dizziness.

Q: What should I do if I miss a dose of Polymyxin B?

Instructions for a missed dose can vary significantly depending on the specific form of the drug being used (systemic vs. topical). Patient information for certain forms describes a procedure where a missed dose is taken as soon as remembered, unless the time is very close to the next scheduled dose.

Q: Is it safe to drink alcohol while using Polymyxin B?

The official labeling does not include a specific drug-alcohol interaction warning for Polymyxin B. However, official labeling notes that alcohol consumption may potentially contribute to side effects like dizziness or drowsiness.

Q: Can I take multivitamins or supplements with Polymyxin B?

Official patient materials consistently state that all prescription drugs, over-the-counter medicines, and supplements must be reviewed by the healthcare provider to check for potential interactions.

Q: Are there any common herbal remedies that should be avoided with Polymyxin B?

Official guidance indicates that all substances being taken, including herbal products and natural supplements, are subject to review by the healthcare provider to ensure a comprehensive review of potential interactions.

Q: What are the specific concerns for older adults using Polymyxin B?

The official warnings indicate that the risk of toxicity is heightened in patients with impaired renal function. Official documents indicate that patients with impaired kidney function must have their dosage adjusted and receive careful monitoring, which may be applicable to older adults.

Q: What happens if I stop using Polymyxin B before the recommended duration?

Regulatory documents contain standard antibiotic warnings stating that stopping the medication early, even if symptoms begin to improve, can increase the risk of developing drug-resistant bacteria. These resistant bacteria may not respond to future treatment.

Q: Is Polymyxin B used to treat urinary tract infections (UTIs)?

Yes, official indications for Polymyxin B include the treatment of urinary tract infections. This use is specified for infections caused by susceptible strains of certain Gram-negative organisms, such as Escherichia coli.

Q: Is there a risk of antibiotic resistance developing with Polymyxin B?

Yes, official regulatory documents warn that the use of any antibacterial drug, including Polymyxin B, carries a risk of the development of drug-resistant bacteria. The warnings emphasize that using the drug when no infection is present increases this risk.

Q: What happens when Polymyxin B enters the body (pharmacokinetics)?

Pharmacological data from regulatory sources show key metrics such as the drug's half-life (approximately 4.3 to 6 hours) and its excretion (about 60% eliminated in urine). The data also indicates that the drug does not easily cross the blood-brain barrier.

Q: Does the brand or manufacturer affect how Polymyxin B works?

Regulatory standards focus on the active ingredient, which is Polymyxin B sulfate. The medication's function is entirely dependent on the chemical structure of this active ingredient, regardless of the brand or manufacturer.

Q: Is it normal to feel a stinging sensation when using Polymyxin B topical treatments?

Yes, patient information for certain topical forms of the medication confirms that a temporary side effect such as burning or stinging may occur upon application.

Q: Has there been recent research on new uses for Polymyxin B?

While the official uses remain consistent, broader regulatory and research contexts indicate that current studies are exploring next-generation polymyxin variants. This research is often focused on finding ways to reduce the drug's known toxicity while maintaining its efficacy.

Q: How is the safety of Polymyxin B monitored by official regulatory bodies?

Official monitoring involves frequent checks of renal function and drug blood levels for patients receiving parenteral therapy. This required process is due to the risk of dose-dependent toxicity.

How should Polymyxin B be stored and disposed of?

Storage and Stability Requirements

Official regulatory documents define distinct storage conditions for Polymyxin B depending on its state. The unreconstituted powder for injection must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light and retained in its carton until use. The container should be kept tightly closed to avoid moisture.

Once the product is prepared as a solution, its storage requirements change significantly. The reconstituted solution must be stored under refrigeration (2 C to 8 C / 36 F to 46 F) and any unused portion must be discarded after 72 hours to maintain stability.

Disposal and Child Safety

Polymyxin B must be kept out of the reach and sight of children. Disposal of all unused, expired, or leftover product, along with any used containers, must be conducted in accordance with local, state, and federal regulations. Regulations explicitly advise that the product should not be emptied into drains or watercourses.

Polymyxin B